ribociclib
novartis
['maintain trial', 'bcsm', 'congrat', 'ribociclib']
super interesting maintain trial results. congrats on this iit presentation . is the improvement because ribociclib is a stronger cdk4/6i than other cdk4/6 inhibitors and it s benefits delayed (rather than using 1st line)? #asco2022 #bcsm 
Breast medical oncologist at Levine Cancer Institute @LevineCancer @LCI_YWBP